Medical device giant Stryker is looking to boost its non-U.S. sales figures with an overhaul of its European business and a growing focus on emerging markets.
Medical device company Stryker (NYSE:SYK) will put a renewed focus on efforts to boost sales in markets outside of the U.S., president & CEO Kevin Lobo told an audience at the J.P. Morgan Healthcare Conference in San Francisco Wednesday.
Those efforts include an overhaul of Stryker's European business and a growing push in emerging markets, Lobo said.
The company got some Wall Street love Wednesday upon releasing its preliminary full year results, predicting per-share earnings of about $4.05-$4.07 on sales of $8.7 billion, a 4.2% increase in revenues over 2011.
Stryker also projected 2013 adjusted EPS in the range of $4.25-$4.40, expecting to take a $100 million hit due to the impact of the medical device tax that took effect at the start of the year.
The news sent SYK shares up 2.5% on the day, along the way hitting a new 52-week high of $58.74 before closing at $58.48.
Part of the company's ongoing strategy involves boosting its non-U.S. sales, Lobo said today.
"Globalization's an enormous opportunity for Stryker, we clearly have room to grow outside the U.S.," he told meeting attendees. "The U.S. is still representative of 65% of our total sales. That is a ratio that hasn't changed in about 10 years."
Endologix is seeking to raise $75 million through sales of convertible notes with 2018 due dates.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
The FDA fines Ethicon's Advanced Sterilization Products business a total of $1.25 million over...
EnteroMedics unveils efficacy and safety results from the 1st 18 months of its 5-year ReCharge...
Medtech titan Medtronic wins European and Australian regulatory approval for next-generation...